On December 12, 2022, the Board of Directors of Adverum Biotechnologies, Inc. appointed Linda Rubinstein as Adverum's Chief Financial Officer. Ms. Rubinstein also assumed the role of Principal Financial Officer and Principal Accounting Officer of Adverum. Ms. Rubinstein replaces John Rakow, who previously served as Acting Chief Financial Officer and Principal Financial Officer, and Nancy Pecota, who previously served as Principal Accounting Officer.

Mr. Rakow and Ms. Pecota ceased their respective roles effective as of December 12, 2022. Mr. Rakow will continue to serve in his role of General Counsel of Adverum. Ms. Rubinstein, age 56, was appointed as Chief Financial Officer on December 12, 2022.

Ms. Rubinstein has served as Partner at FLG Partners, LLC, a chief financial officer and board advisory services firm, since September 2010, where she assists clients with strategic planning, executes financing transactions, creates business plans and develops corporate and investor positioning. During the previous five years, Ms. Rubinstein has served as consulting chief financial officer or financial advisor to multiple biotech companies, including Alector, Apexigen, ArmaGen, Five Prime Therapeutics, Kezar Life Sciences, Medikine, RenovoRx and Sublimity Therapeutics. Ms. Rubinstein earned a B.A. and a M.A. from University of California, Los Angeles.